Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease

详细信息	查看全文 | 推荐本文 |

• 作者：Bor-Jen Lee ; M.D.^a ; ^b ; Yi-Chia Huang ; Ph.D.^a ; ^c ; Shu-Ju Chen ; Ph.D.^d ; Ping-Ting Lin ; Ph.D.^a ; ^c ; ^{apt810@csmu.edu.tw}
• 关键词：Coenzyme Q10 ; Inflammation ; High-sensitivity C-reactive protein ; Interleukin-6 ; Coronary artery disease ; Antioxidant
• 刊名：Nutrition
• 出版年：2012
• 期刊代码：81_08999007
• 类别：abs
• 出版时间：July-August, 2012
• 卷：28
• 期：7-8
• 页码：767-772
• 文件大小：369 K

摘要

Objective

The purpose of this study was to investigate the effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein [hs-CRP], interleukin-6 [IL-6], and homocysteine) in patients with coronary artery disease (CAD).

Methods

Patients with CAD (n = 51) were randomly assigned to a placebo group (n = 14) or one of two coenzyme Q10-supplemented groups (60 mg/d, Q10-60 group, n = 19; 150 mg/d, Q10-150 group, n = 18). The intervention was administered for 12 wk. Plasma coenzyme Q10 concentration, inflammatory markers (hs-CRP, IL-6, and homocysteine), malondialdehyde, and superoxide dismutase activities were measured.

Results

Forty subjects with CAD completed the intervention study. The plasma coenzyme Q10 concentration increased significantly in the Q10-60 and Q10-150 groups (P < 0.01). After 12 wk of intervention, the inflammatory marker IL-6 (P = 0.03) was decreased significantly in the Q10-150 group. Subjects in the Q10-150 group had significantly lower malondialdehyde levels and those in the Q10-60 (P = 0.05) and Q10-150 (P = 0.06) groups had greater superoxide dismutase activities. Plasma coenzyme Q10 was inversely correlated with hs-CRP (r = 鈭?.20, P = 0.07) and IL-6 (r = 鈭?.25, P = 0.03) at baseline. After supplementation, plasma coenzyme Q10 was significantly correlated with malondialdehyde (r = 鈭?.35, P < 0.01) and superoxide dismutase activities (r = 0.52, P < 0.01). However, there was no correlation between coenzyme Q10 and homocysteine.

Conclusion

Coenzyme Q10 supplementation at a dosage of 150 mg appears to decrease the inflammatory marker IL-6 in patients with CAD.